Cardiogenetics | Aims and Scope Update

To further enhance the quality of Cardiogenetics and the papers published in it, under the guidance of our Editor-in-Chief, Dr. Giuseppe Limongelli, the journal has updated and revised its aims and scope. The original scope and the updated version are listed below:

Scope (new version):

Scope (old version):

As an essential resource to general physicians, cardiologists, and geneticists, Cardiogenetics’ primary purpose is to report original research in the following areas:

- Clinical and molecular aspects of inherited heart diseases (IHDs): genotype–phenotype findings; follow-up data from IHD clinics; clinical findings from large and informative families with IHDs; studies on molecular imaging in IHDs;

- Clinical and molecular aspects of rare diseases: clinical imaging and molecular findings of rare diseases (RDs) with cardiovascular involvement;

- Pharmacogenetics and pharmacogenomics: studies involving new drugs or well-known therapies in IHDs, RDs, and cardiovascular medicine; genetic/genomic profile and response to therapies;

- Stem cell studies: clinical trials and experimental studies involving cell studies/cell therapy;

- Diagnostic methods, including sequencing studies;

- Bioinformatics and statistical methods in genetics;

- Personalized medicine and therapies (gene therapy and gene editing);

- Molecular biology and pathophysiology of genetic and genomic diseases: biology of cells; pathways and systems; epigenetics and gene regulation; biology and pathophysiology of specific genes and non-coding DNA;

- Polygenic/multifactorial disorders;

-Cellular electrophysiological studies related to inherited arrhythmogenic conditions;

-Imaging in cardiogenetics;

-Mutation reports.

A space will be given to negative studies in cardiogenetics: this space will be dedicated to clinical, molecular, cellular, and pharmacological studies with a solid scientific background that lead to negative results.